These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A radiation oncologist's and thoracic surgeon's view on the role of stereotactic ablative radiotherapy for operable lung cancer. Timmerman RD, Fernando HC. Semin Thorac Cardiovasc Surg; 2013 Dec; 25(1):8-13. PubMed ID: 23800524 [Abstract] [Full Text] [Related]
12. Stereotactic radiosurgery for early stage non-small cell lung cancer: rationale, patient selection, results, and complications. Christie NA, Pennathur A, Burton SA, Luketich JD. Semin Thorac Cardiovasc Surg; 2008 Dec; 20(4):290-7. PubMed ID: 19251167 [Abstract] [Full Text] [Related]
13. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA. Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e291-7. PubMed ID: 21640503 [Abstract] [Full Text] [Related]
14. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Salazar OM, Sandhu TS, Lattin PB, Chang JH, Lee CK, Groshko GA, Lattin CJ. Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):707-15. PubMed ID: 18455322 [Abstract] [Full Text] [Related]
15. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer. Abbas G, Danish A, Krasna MJ. Surg Oncol Clin N Am; 2016 Jul 01; 25(3):553-66. PubMed ID: 27261915 [Abstract] [Full Text] [Related]
16. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome. Lee DS, Kim YS, Yoo IeR, Kang YN, Kim SJ, Oh JK, Kim YK, Wang YP, Park JG, Kang JH, Han DH, Ahn MI, Lee KY. Lung Cancer; 2013 May 01; 80(2):172-8. PubMed ID: 23489556 [Abstract] [Full Text] [Related]
17. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Ferrero C, Badellino S, Filippi AR, Focaraccio L, Giaj Levra M, Levis M, Moretto F, Torchio R, Ricardi U, Novello S. Lung Cancer; 2015 Sep 01; 89(3):350-6. PubMed ID: 26164208 [Abstract] [Full Text] [Related]
18. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Chang JY, Bezjak A, Mornex F, IASLC Advanced Radiation Technology Committee. J Thorac Oncol; 2015 Apr 01; 10(4):577-85. PubMed ID: 25514807 [Abstract] [Full Text] [Related]
19. Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy. Dan T, Williams NL. Surg Oncol Clin N Am; 2017 Jul 01; 26(3):393-403. PubMed ID: 28576179 [Abstract] [Full Text] [Related]
20. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. Westover KD, Iyengar P, Sharma AN, Timmerman R. Lung Cancer; 2015 Aug 01; 89(2):87-93. PubMed ID: 26028304 [Abstract] [Full Text] [Related] Page: [Next] [New Search]